Covid-19: Hydroxychloroquine does not benefit hospitalised patients, UK trial finds
Hydroxychloroquine does not reduce the risk of dying or improve other outcomes in hospitalised patients treated for covid-19, preliminary results from the UK RECOVERY trial have shown. Announcing the results, Martin Landray, the study’s deputy chief investigator, said, “We have concluded that there...
Saved in:
| Published in | BMJ Vol. 369; p. m2263 |
|---|---|
| Main Author | |
| Format | Journal Article Web Resource |
| Language | English |
| Published |
London
British Medical Journal Publishing Group
08.06.2020
BMJ Publishing Group LTD |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Hydroxychloroquine does not reduce the risk of dying or improve other outcomes in hospitalised patients treated for covid-19, preliminary results from the UK RECOVERY trial have shown. Announcing the results, Martin Landray, the study’s deputy chief investigator, said, “We have concluded that there is no beneficial effect of hydroxychloroquine in patients hospitalised with covid-19. We have therefore decided to stop enrolling participants to the hydroxychloroquine arm with immediate effect.” The data show the death rate at 28 days in covid-19 patients taking hydroxychloroquine is 25.7% compared with 23.5% in patients provided with only usual hospital care (hazard ratio 1.11 (95% confidence interval 0.98-1.26); P=0.10). So far 1542 patients in the trial have been randomised to hydroxychloroquine and 3132 patients randomised to usual care alone. There was also no evidence that hydroxychloroquine impacted on length of … |
|---|---|
| AbstractList | Hydroxychloroquine does not reduce the risk of dying or improve other outcomes in hospitalised patients treated for covid-19, preliminary results from the UK RECOVERY trial have shown. Announcing the results, Martin Landray, the study’s deputy chief investigator, said, “We have concluded that there is no beneficial effect of hydroxychloroquine in patients hospitalised with covid-19. We have therefore decided to stop enrolling participants to the hydroxychloroquine arm with immediate effect.” The data show the death rate at 28 days in covid-19 patients taking hydroxychloroquine is 25.7% compared with 23.5% in patients provided with only usual hospital care (hazard ratio 1.11 (95% confidence interval 0.98-1.26); P=0.10). So far 1542 patients in the trial have been randomised to hydroxychloroquine and 3132 patients randomised to usual care alone. There was also no evidence that hydroxychloroquine impacted on length of … The data show the death rate at 28 days in covid-19 patients taking hydroxychloroquine is 25.7% compared with 23.5% in patients provided with only usual hospital care (hazard ratio 1.11 (95% confidence interval 0.98-1.26); P=0.10). A huge upsurge in hospitalised cases around a month ago meant that the amount of data on hydroxychloroquine had increased very recently and “the picture has changed,” said Landray, professor of medicine and epidemiology at the Nuffield Department of Population Health at the University of Oxford. Last week a Lancet paper,2 which suggested that use of hydroxychloroquine to treat covid-19 could increase risk of death, was retracted because of questions over the provenance of the data.3 The paper had prompted the World Health Organization to pause the hydroxychloroquine arm of its Solidarity trial which is testing possible treatments for covid-19, although it reversed this decision following the retraction.4 The RECOVERY trial’s chief investigator Peter Horby, professor of emerging infectious diseases and global health in the Nuffield Department of Medicine, University of Oxford, said that he had spoken to WHO about the results. |
| Author | Torjesen, Ingrid |
| Author_xml | – sequence: 1 givenname: Ingrid surname: Torjesen fullname: Torjesen, Ingrid |
| BookMark | eNp90V1LwzAUBuAgip-78B8EVFCwek6yNq13MvzCgRe665I2Z5jRJbPpxP17MycqCl7lEB5yXvLusHXnHTG2j3CGKLPzajo5mwqRyTW2jSrNEsylXP8xb7FeCBMAEFLlRZZusi0pUpQ5wjZ7HPhXaxIsLvjtwrT-bVE_N771L3PriBtPgTvf8YocjW3Hn32Y2U43NpDhM91Zcl045aN73rVWN3xsnQl7bGOsm0C9z3OXja6vnga3yfDh5m5wOUyqPoou0VIJyIUmBVpSnQqNVYynlSlEBRKN0AJJKwU1CEVoMq2gr6DIU8qN1HKXHa_enS3zUujKqQ01NY125OehFH1EBNUXRaQHv-jEz1sX00UV0-RKZfi_QkgB4g9GdbJSdetDaGlczlo71e2iRCiXlZSxkvKjkmgPV3Z59R87-mZfO_-6d3Ynk8k |
| CitedBy_id | crossref_primary_10_1038_s41598_020_71282_6 crossref_primary_10_1136_bmj_m3046 crossref_primary_10_1186_s12962_021_00296_2 crossref_primary_10_1038_s41591_020_0999_9 crossref_primary_10_1136_bmj_m2650 crossref_primary_10_1016_j_virusres_2020_198073 crossref_primary_10_1136_bmj_m2670 crossref_primary_10_1080_13102818_2020_1847683 crossref_primary_10_33450_fpn_2020_11_001 crossref_primary_10_1136_bmj_m2378 crossref_primary_10_1007_s40259_023_00611_8 crossref_primary_10_1016_j_transci_2021_103154 crossref_primary_10_1097_CNQ_0000000000000346 crossref_primary_10_1038_s41598_021_81617_6 crossref_primary_10_1002_jmv_26442 crossref_primary_10_21931_RB_2020_05_04_2 crossref_primary_10_1186_s13098_022_00857_2 crossref_primary_10_1016_j_ejmech_2021_113789 crossref_primary_10_1177_2472555220979579 crossref_primary_10_2459_JCM_0000000000001099 crossref_primary_10_1007_s42770_020_00395_x crossref_primary_10_15406_jlprr_2020_07_00228 crossref_primary_10_1002_acr_25331 crossref_primary_10_1007_s00210_020_01964_5 crossref_primary_10_1136_bmj_m2422 crossref_primary_10_1186_s12929_020_00703_5 crossref_primary_10_14336_AD_2020_1124 crossref_primary_10_5155_eurjchem_12_2_222_234_2084 crossref_primary_10_3389_fphar_2020_01330 crossref_primary_10_14814_phy2_14649 |
| Cites_doi | 10.1136/bmj.m2242 10.1136/bmj.m2224 10.1136/bmj.m1626 |
| ContentType | Journal Article Web Resource |
| Copyright | Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to 2020. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.bmj.com/company/legal-information Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go tohttp://group.bmj.com/group/rights-licensing/permissions2020BMJ |
| Copyright_xml | – notice: Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to – notice: 2020. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.bmj.com/company/legal-information – notice: Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go tohttp://group.bmj.com/group/rights-licensing/permissions2020BMJ |
| DBID | AAYXX CITATION COVID 3V. 7RV 7X7 7XB 88I 8AF 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AFKRA ASE AZQEC BBNVY BENPR BHPHI BTHHO CCPQU DWQXO FPQ FYUFA GHDGH GNUQQ GUQSH HCIFZ K6X K9. KB0 LK8 M2O M2P M7P MBDVC NAPCQ PQEST PQQKQ PQUKI PRINS Q9U 7X8 |
| DOI | 10.1136/bmj.m2263 |
| DatabaseName | CrossRef Coronavirus Research Database ProQuest Central (Corporate) Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) Science Database (Alumni Edition) STEM Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni Edition) ProQuest Central (Alumni) ProQuest Central British Nursing Index ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection BMJ Journals ProQuest One Community College ProQuest Central British Nursing Index (BNI) (1985 to Present) Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep SciTech Premium Collection British Nursing Index ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Biological Sciences Research Library ProQuest Science Journals Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic |
| DatabaseTitle | CrossRef Coronavirus Research Database Research Library Prep ProQuest Central Student ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest AP Science ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Central China ProQuest Central Health Research Premium Collection Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest Research Library ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition British Nursing Index ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition BMJ Journals ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Coronavirus Research Database Research Library Prep |
| Database_xml | – sequence: 1 dbid: COVID name: Coronavirus Research Database url: https://proxy.k.utb.cz/login?url=https://search.proquest.com/coronavirus sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1756-1833 |
| EndPage | m2263 |
| ExternalDocumentID | 10_1136_bmj_m2263 ttps://bmj.com/content/369/bmj.m2263.full |
| Genre | News |
| GeographicLocations | United Kingdom--UK |
| GeographicLocations_xml | – name: United Kingdom--UK |
| GroupedDBID | 0R~ 23N 39C 4.4 40O 53G 5GY 7RV 7X7 88I 8AF 8F7 8FE 8FH 8FI 8FJ 8G5 AACGO AANCE AAWJN ABBHK ABIVO ABJNI ABPLY ABTLG ABUWG ABVAJ ABXSQ ACGFS ACGOD ACMFJ ACPRK ADACV AEUPB AEXZC AFKRA AGFXO AHMBA AHNKE AHQMW AJYBZ ALIPV ALMA_UNASSIGNED_HOLDINGS AZQEC BBNVY BENPR BHPHI BPHCQ BTHHO C45 CCPQU CS3 DCCCD DWQXO EBS EJD F5P FYUFA GNUQQ GUQSH H13 HAJ HCIFZ HMCUK HZ~ IPSME JAAYA JBMMH JENOY JHFFW JKQEH JLS JLXEF JPM JSG JST L7B LK8 M2O M2P M7P NAPCQ NXWIF O9- OVD PQQKQ PROAC R53 RHF RHI RMJ RV8 SA0 TEORI UKHRP VVN WOQ YFH YQY AAYXX CITATION COVID 3V. 7XB 8FK ASE FPQ K6X K9. MBDVC PQEST PQUKI PRINS Q9U 7X8 |
| ID | FETCH-LOGICAL-b412t-a372082ae70a3ec52a1b965a7d92b031d2a21ea770c027e1d6a70470985e8d3a3 |
| IEDL.DBID | 7X7 |
| ISSN | 1756-1833 |
| IngestDate | Fri Oct 25 08:54:22 EDT 2024 Thu Oct 10 20:52:36 EDT 2024 Thu Oct 10 16:19:56 EDT 2024 Fri Aug 23 00:38:38 EDT 2024 Wed Aug 21 03:31:27 EDT 2024 Tue Oct 08 17:52:22 EDT 2024 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-b412t-a372082ae70a3ec52a1b965a7d92b031d2a21ea770c027e1d6a70470985e8d3a3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://www.bmj.com/content/bmj/369/bmj.m2263.full.pdf |
| PMID | 32513810 |
| PQID | 2410500378 |
| PQPubID | 4686279 |
| ParticipantIDs | proquest_miscellaneous_2411107429 proquest_journals_2441287761 proquest_journals_2410500378 crossref_primary_10_1136_bmj_m2263 bmj_primary_10_1136_bmj_m2263 bmj_journals_10_1136_bmj_m2263 |
| PublicationCentury | 2000 |
| PublicationDate | 20200608 2020-06-08 |
| PublicationDateYYYYMMDD | 2020-06-08 |
| PublicationDate_xml | – month: 6 year: 2020 text: 20200608 day: 8 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London |
| PublicationTitle | BMJ |
| PublicationTitleAbbrev | BMJ |
| PublicationYear | 2020 |
| Publisher | British Medical Journal Publishing Group BMJ Publishing Group LTD |
| Publisher_xml | – name: British Medical Journal Publishing Group – name: BMJ Publishing Group LTD |
| References | Wilkinson (ref1) 2020; 369 Mahase (ref5) 2020; 369 Iacobucci (ref3) 2020; 369 Iacobucci 2020; 369 Wilkinson 2020; 369 Mahase 2020; 369 2020060809094316000_369.jun08_10.m2263.2 2020060809094316000_369.jun08_10.m2263.3 2020060809094316000_369.jun08_10.m2263.1 2020060809094316000_369.jun08_10.m2263.4 2020060809094316000_369.jun08_10.m2263.5 |
| References_xml | – volume: 369 start-page: m1626 year: 2020 ident: ref1 article-title: RECOVERY trial: the UK covid-19 study resetting expectations for clinical trials publication-title: BMJ contributor: fullname: Wilkinson – volume: 369 start-page: m2224 year: 2020 ident: ref3 article-title: Covid-19: Validity of key studies in doubt after leading journals issue expressions of concern publication-title: BMJ contributor: fullname: Iacobucci – volume: 369 start-page: m2242 year: 2020 ident: ref5 article-title: Covid-19: Hydroxychloroquine was ineffective as postexposure prophylaxis, study finds publication-title: BMJ contributor: fullname: Mahase – volume: 369 start-page: m1626 year: 2020 article-title: RECOVERY trial: the UK covid-19 study resetting expectations for clinical trials publication-title: BMJ contributor: fullname: Wilkinson – volume: 369 start-page: m2224 year: 2020 article-title: Covid-19: Validity of key studies in doubt after leading journals issue expressions of concern publication-title: BMJ contributor: fullname: Iacobucci – volume: 369 start-page: m2242 year: 2020 article-title: Covid-19: Hydroxychloroquine was ineffective as postexposure prophylaxis, study finds publication-title: BMJ contributor: fullname: Mahase – ident: 2020060809094316000_369.jun08_10.m2263.5 doi: 10.1136/bmj.m2242 – ident: 2020060809094316000_369.jun08_10.m2263.3 doi: 10.1136/bmj.m2224 – ident: 2020060809094316000_369.jun08_10.m2263.4 – ident: 2020060809094316000_369.jun08_10.m2263.1 doi: 10.1136/bmj.m1626 – ident: 2020060809094316000_369.jun08_10.m2263.2 |
| SSID | ssj0002378965 |
| Score | 2.5140622 |
| Snippet | Hydroxychloroquine does not reduce the risk of dying or improve other outcomes in hospitalised patients treated for covid-19, preliminary results from the UK... The data show the death rate at 28 days in covid-19 patients taking hydroxychloroquine is 25.7% compared with 23.5% in patients provided with only usual... |
| SourceID | proquest crossref bmj |
| SourceType | Aggregation Database Publisher |
| StartPage | m2263 |
| SubjectTerms | Azithromycin Coronaviruses COVID-19 Dexamethasone Hospitals Hydroxychloroquine Infectious diseases Lopinavir News Patients Prophylaxis Ritonavir |
| Title | Covid-19: Hydroxychloroquine does not benefit hospitalised patients, UK trial finds |
| URI | http://dx.doi.org/10.1136/bmj.m2263 https://www.proquest.com/docview/2410500378 https://www.proquest.com/docview/2441287761 https://search.proquest.com/docview/2411107429 |
| Volume | 369 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1dS8MwMOgE8UX8xOkcUXy02iZt0_oiOpWp-IE62dtImpQp2E7bPfjvveuyyUD31JArKble7jt3hBwIL1A-1wY0t9R1fCEDRzHlO7EKYimTlMMMZlvch-2Of9MNutbhVti0yjFPrBi1zhP0kR-DGAJWKsDqPh18Otg1CqOrtoXGPFnwmBtiSpfoiomPhXERxWFgCwp5PDxWH-9HH6BxYJFAGE8Lo2leXAmYqxWybDVDejb6latkzmRrZPHOxr7XyXML78w5XnxC298as0-SPhjbsBiAqc5NQbO8pAqYV_pW0r5tCPJWGE1t9dTikHZuadWog2KwutggnavLl1bbsS0RHAXbLx2JTWUiJo1wJTdJwKSnYIdS6JgpOJ-aSeYZKYSbgL1pPB1K4frCjaPARJpLvklqWZ6ZLUIV19qNQVhJlviRH6swUVFVr8ukTDG_TpqAoZ4l6aJXWQs87OFkhcI62cXxYFQV4y_4_hi5s15qjNH--ymGuadYGSf6BzwmhTrZm4DhWGCsQ2YmH1ZLoGUL0nZ79hI7ZImhCY2OlahBauXX0OyCnlGqZkVMTbJwfnn_-ATP1sPr9cUPV_jUEQ |
| link.rule.ids | 315,783,787,12068,21400,27936,27937,31731,31732,33756,33757,38528,43322,43817,43907,74073,74630 |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NS8MwFA9-gHoRP3HqNIpH69qkbVovorIxnQ5RB7uNpEmZgq3aevC_970umwx0t5BXUvqavO_8HiEnwguUz7UByy11HV_IwFFM-U6sgljKJOUwg9UW3bDd82_7Qd8G3ApbVjmWiZWg1nmCMfIGqCEQpQK87ov3Dwe7RmF21bbQmCeLCFUFztfiVbP78DiJsjAuojgMLKSQx8OGens9ewObA2ECYTytjqalcaViWmtk1dqG9HL0M9fJnMk2yNK9zX5vkqdrvDXnePE5bX9rrD9JhuBuw2JApjo3Bc3ykioQX-lLSYe2JchLYTS1-KnFKe11aNWqg2K6utgivVbz-brt2KYIjgIGlI7EtjIRk0a4kpskYNJT8IVS6JgpOKGaSeYZKYSbgMdpPB1K4frCjaPARJpLvk0WsjwzO4QqrrUbg7qSLPEjP1ZhoqIKscukTDG_Rg6AQwO7qYtB5S_wcICTFQtrpI7j9xEuxl_04zFzZz20P2b776sYVp8iNk70D3m8GWrkaEKGg4HZDpmZ_KtaAn1b0Le7s5c4JMvt5_u7wd1Nt7NHVhg61BhmifbJQvn5ZepgdZTqwG6tH8ac1TU |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1dT9sw8LQVCe0FjQ1E-TRoj2RNbCdOeEHAWhXYKgSrxFtlx44AqUlZwsP-_e6CW4TEeLN80UW5nO_bdwDfVBQbKaxDy60IA6l0HBhuZJCZONM6LwTuULXFKBmO5cVtfOvrn2pfVjmXia2gtlVOMfIeqiEUpQq97l7hyyKufgyOZ48BTZCiTKsfp_ERlpRMRNiBpdP-6Op6EXHhQqVZEvv2QpFIemb68H2K9ge1DMT1a9X0WjK36mbwGVa8nchOnn_sKnxw5RdY_uUz4V_h5oxu0AVRdsSGfy3VouR36HojMgQzW7malVXDDIqy4r5hd348yH3tLPO9VOtDNr5k7dgORqnreg3Gg_7vs2HgByQEBonRBJpGzKRcOxVq4fKY68jgF2plM27wtFqueeS0UmGO3qeLbKJVKFWYpbFLrdBiHTplVboNYEZYG2aoujTPZSozk-Qmbbt3uYIbLruwixSaeAavJ63vIJIJbbYk7MIOrWfPPTLegh_MifveQ9tzsr-8ilMlKvXJSf8DnjNGF_YXYDwklPnQpaueWhTk56Lu3XwfxR4sI1dNfp6PLrfgEyffmiIu6TZ0mj9PbgcNkMbses76B6NQ2WM |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Covid-19%3A+Hydroxychloroquine+does+not+benefit+hospitalised+patients%2C+UK+trial+finds&rft.jtitle=BMJ+%28Online%29&rft.au=Torjesen%2C+Ingrid&rft.date=2020-06-08&rft.pub=BMJ+Publishing+Group+LTD&rft.eissn=1756-1833&rft.volume=369&rft.spage=m2263&rft_id=info:doi/10.1136%2Fbmj.m2263&rft.externalDBID=HAS_PDF_LINK |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-1833&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-1833&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-1833&client=summon |